There are fewer studies on the bleeding risk of the currently administered bivalirudin bolus
injection dose and the safety of bivalirudin in patients with CKD. A non-inferiority,
randomized, stratified controlled trial study has been conducted to evaluate the
non-inferiority and safety of the low dose (80%) bolus injections of bivalirudin in patients
with or without CKD.This study will provide a safe, effective and economical anticoagulation
strategy.